Read what Sheldon Sloan, MD, M Bioethics, Abivax Chief Medical Officer had to say about the role of small molecule drugs in #autoimmune and chronic conditions like #ulcerativecolitis with European Pharmaceutical Review:
Learn how Abivax's small molecule treatment could benefit UC patients and why these drugs hold promise to treat autoimmune diseases. #clinicaltrials #smallmolecules #EPRTalks
Exciting findings from EULAR 2024 Annual Meeting reveal that Canakinumab offers a groundbreaking treatment approach for systemic juvenile idiopathic arthritis (sJIA) patients. This study shows sustained disease control without glucocorticoids, with fever controlled after just one injection. Dr. Horneff's research paves the way for steroid-free management of sJIA. Read more for insights on this promising first-line monotherapy. #rheumatology #sJIA #Canakinum
A full-slide deck on Solitano et al’s guidance for #JAK inhibitor therapy in high-risk IMID patients is now available on the Immune-mediated Inflammatory Disease forum. This study highlighted the need for individual assessment of patient risk profiles before initiating JAK inhibitor treatment. Head to the #IMIDforum to access this valuable free resource and more! https://lnkd.in/eE4ytRhG #axSpA #JAKi #Guidance
👉 Check this #FeaturedPaper: "The Impact of the CB2 Cannabinoid Receptor in Inflammatory Diseases: An Update" by Rakotoarivelo et al. (Université Laval, Canada) 📌#inflammation #cannabinoid #endocannabinoid #RecommendedPaper #RecommendedReview
Pharmacist | Mphil pharmacy Practice | Medical Writer | Health and Fitness Writer | Research Writing | Blogs and Posts | Quality over Quantity
🤔🤔Let's recall our knowledge,my 𝐂𝐨𝐦𝐦𝐞𝐧𝐭 𝐬𝐞𝐜𝐭𝐢𝐨𝐧 is waiting for your responses,🗣🗣 ✍𝑶𝒇𝒇-𝒍𝒂𝒃𝒆𝒍 𝒖𝒔𝒆: Polycystic ovarian syndrome ✍𝑺𝒊𝒅𝒆-𝑬𝒇𝒇𝒆𝒄𝒕𝒔: Stomach ache, loss of appetite, Diarrhoea, 𝑾𝒆𝒊𝒈𝒉𝒕 𝒍𝒐𝒔𝒔, Metallic taste in mouth,Vitamin B12 deficiency ✍𝑪𝒐𝒏𝒕𝒓𝒂𝒊𝒏𝒅𝒊𝒄𝒂𝒕𝒊𝒐𝒏: This drug is contraindicated in renal dysfunction due to risk of Lactic acidosis.🚫 🔥🔥𝑯𝒊𝒏𝒕: This #drug is used commonly for treating one of the #major chronic #metabolic disease. ⏩𝐃𝐨 𝐜𝐨𝐦𝐦𝐞𝐧𝐭 𝐲𝐨𝐮𝐫 𝐚𝐧𝐬𝐰𝐞𝐫 𝐚𝐧𝐝 #share 𝐰𝐢𝐭𝐡 𝐲𝐨𝐮𝐫 #network
#PulmonaryArterialHypertension (PAH) is one of the rare #cardiovascular diseases. It is a form of a broader condition known as #PulmonaryHypertension, which is high blood pressure in the lungs. Symptoms of PAH are similar to other #lung diseases including #Asthma, #COPD and can also mimic #HeartFailure. Thus, often there is a delay in diagnosing PAH of up to two or more years. #PharmaACE #Pharma #Analytics #Consulting #LungDisease #RareDisease #RareDiseaseDay
Defining a “clinically distinct” target population and addressing the limitations of trial evidence are just two challenges manufacturers face when demonstrating the value of drugs for treating rare diseases. Our whitepaper explores seven key challenges in this area and offers practical approaches to overcome them. Read it now to learn more: https://buff.ly/3SqiHOx #LumanityPerspectives #HTA #HEOR #RareDiseases
Bronchiectasis/NTM patient advocate, educator, author and influencer working with companies & educational institutions to recruit participants for clinical trials, surveys, interviews and focus groups
Insmed said its experimental drug to treat a type of chronic lung disease helped significantly reduce respiratory symptoms such as chronic cough in a late-stage study. The drug candidate, brensocatib, is being developed to treat patients with non-cystic fibrosis bronchiectasis, a chronic lung condition where the walls of the airways are widened due to inflammation and infection. Bronchiectasis affects about 450,000 patients in the United States, and causes symptoms including excessive sputum production, shortness of breath, and repeated respiratory infections, according to Insmed. The company said it plans to file a marketing application for brensocatib with the U.S. Food and Drug Administration in the fourth quarter of this year, and it expects to launch the drug in mid-2025. Source:Reuters #bronchiectasisdrug #BronchiectasisTreatment #StayTheCourse #HaveHope #HaveFaith #DoTheWork #AirwayClearance #Exercise #HealthyEating #thebeclearmethodthebeclearmethodtolivingwithbronchiectasis #LindaEsposito
It’s #AtopicEczemaDay. Dedicated to developing novel therapies for patients affected by #autoimmunedisorders, Nektar is evaluating our novel regulatory T-cell selective IL-2 conjugate, REZPEG, for potential treatment of inflammatory skin diseases, including #atopicdermatitis. Learn more: https://bit.ly/48e4NF2
Clinical characteristics of Autoimmune Hepatitis with #MAFLD are NOT the same as those without MAFLD. 👉https://lnkd.in/deUzgS4N
Want to find out about the disease modifying drugs (DMDs) available to treat multiple sclerosis (MS)? MS Decisions is a guide to the DMDs approved for treating relapsing remitting MS in the UK. Click the link below to learn more. https://lnkd.in/eubDsF9g
